The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Anti‐JC virus antibodies: Implications for PML Risk Stratification
Abstract
Objective: A study was undertaken to establish an enzyme‐linked immunosorbent assay (ELISA) to detect JC virus (JCV)‐specific antibodies in multiple sclerosis (MS) patients, and to evaluate its potential utility for identifying patients at higher or lower risk (ie, risk stratification) of developing progressive multifocal leukoencephalopathy (PML). Methods: A 2‐step assay for detecting and confirming the presence of anti‐JCV antibodies in human serum and plasma was developed and demonstrated to be both sensitive and specific. ELISA cutpoints were statistically established using sera from >800 MS patients from natalizumab clinical studies. Subsequently, this assay was used to determine the presence of anti‐JCV antibodies in natalizumab‐treated PML patients where serum samples were collected 16‐180 months prior to the diagnosis of PML. Results: In our evaluation of natalizumab‐treated MS patients, 53.6% tested positive for anti‐JCV antibodies, with a 95% confidence interval of 49.9 to 57.3%. The false‐negative rate of the ELISA was calculated to be approximately 2.5%, with an upper 1‐sided confidence limit of 4.4%. Notably, we observed anti‐JCV antibodies in all 17 available pre‐PML sera samples, which was significantly different from the 53.6% seropositivity observed in the overall MS study population (p < 0.0001). Interpretation: This 2‐step assay provides a means to classify MS patients as having detectable or not detectable levels of anti‐JCV antibodies. The finding that all 17 of the pre‐PML samples that were available tested seropositive, and none tested seronegative, warrants further research on the clinical utility of the anti‐JCV antibody assay as a potential tool for stratifying MS patients for higher or lower risk of developing PML. Ann Neurol 2010
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1994) · doi:10.1201/9780429246593 · Cited by 40,500
An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1993) · doi:10.1007/978-1-4899-4541-9 · Cited by 21,230
Kleinschmidt-DeMasters, B. K., & Tyler, K. L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051782 · Cited by 1,072
Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease
Van Assche, G., Van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M., Verbeeck, J., Geboes, K., Robberecht, W., & Rutgeerts, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051586 · Cited by 1,060
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
Langer-Gould, A., Atlas, S. W., Green, A. J., Bollen, A. W., & Pelletier, D. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051847 · Cited by 1,034
Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors
Egli, A., Infanti, L., Dumoulin, A., Buser, A., Samaridis, J., Stebler, C., Gosert, R., & Hirsch, H. H. (2009) · The Journal of Infectious Diseases · doi:10.1086/597126 · Cited by 781
Seroepidemiology of Human Polyomaviruses
Kean, J. M., Rao, S., Wang, M., & Garcea, R. L. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000363 · Cited by 731
Clifford, D. B., DeLuca, A., Simpson, D. M., Arendt, G., Giovannoni, G., & Nath, A. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70028-4 · Cited by 636
Knowles, W. A., Pipkin, P., Andrews, N., Vyse, A., Minor, P., Brown, D. W. G., & Miller, E. (2003) · Journal of Medical Virology · doi:10.1002/jmv.10450 · Cited by 586
Chesters, P. M., Heritage, J., & McCance, D. J. (1983) · Journal of Infectious Diseases · doi:10.1093/infdis/147.4.676 · Cited by 532
Padgett, B. L., & Walker, D. L. (1973) · Journal of Infectious Diseases · doi:10.1093/infdis/127.4.467 · Cited by 479
Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies
Major, E. O. (2010) · Annual Review of Medicine · doi:10.1146/annurev.med.080708.082655 · Cited by 437
Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders
Martin, S. I., Marty, F. M., Fiumara, K., Treon, S. P., Gribben, J. G., & Baden, L. R. (2006) · Clinical Infectious Diseases · doi:10.1086/504811 · Cited by 272
JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy
Koralnik, I. J., Boden, D., Mai, V. X., Lord, C. I., & Letvin, N. L. (1999) · Neurology · doi:10.1212/wnl.52.2.253 · Cited by 256
Progressive Multifocal Leukoencephalopathy after Natalizumab Monotherapy
Lindå, H., von Heijne, A., Major, E. O., Ryschkewitsch, C., Berg, J., Olsson, T., & Martin, C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810316 · Cited by 218
Antonsson, A., Green, A. C., Mallitt, K., O'Rourke, P. K., Pawlita, M., Waterboer, T., & Neale, R. Ε. (2010) · Journal of General Virology · doi:10.1099/vir.0.020115-0 · Cited by 154
Neff, R. T., Hurst, F. P., Falta, E. M., Bohen, E. M., Lentine, K. L., Dharnidharka, V. R., Agodoa, L. Y. C., Jindal, R. M., Yuan, C. M., & Abbott, K. C. (2008) · Transplantation · doi:10.1097/tp.0b013e31818b62c8 · Cited by 140
Sunyaev, S. R., Lugovskoy, A. A., Simon, K. J., & Gorelik, L. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000368 · Cited by 139
Self-citationRearrangement Patterns of JC Virus Noncoding Control Region from Different Biological Samples
Pietropaolo, V., Videtta, M., Fioriti, D., Mischitelli, M., Arancio, A., Orsi, N., & Degener, A. (2003) · Journal of NeuroVirology · doi:10.1080/jnv.9.6.603.611 · Cited by 45
Rollison, D. E. M., Engels, E. A., Halsey, N. A., Shah, K. V., Viscidi, R. P., & Helzlsouer, K. J. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0728 · Cited by 30
Cited by
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S., Natarajan, A., Lee, S., Plavina, T., Scanlon, J. V., Sandrock, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107829 · Cited by 1,242
Self-citationPlavina, T., Subramanyam, M., Bloomgren, G., Richman, S., Pace, A., Lee, S., Schlain, B., Campagnolo, D., Belachew, S., & Ticho, B. (2014) · Annals of Neurology · doi:10.1002/ana.24286 · Cited by 438
Self-citationMultiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies
Wingerchuk, D. M., & Carter, J. L. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.11.002 · Cited by 416
A cornucopia of human polyomaviruses
DeCaprio, J. A., & Garcea, R. L. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro2992 · Cited by 363
Immunology of Relapse and Remission in Multiple Sclerosis
Steinman, L. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120227 · Cited by 330
Metadata
- Authors
- Gorelik, L., Lerner, M., Bixler, S., Crossman, M., Schlain, B., Simon, K., Pace, A., Cheung, A., Chen, L. L., Berman, M., Zein, F., Wilson, E., Yednock, T., Sandrock, A., Goelz, S. E., & Subramanyam, M.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2010-08-24
- Volume
- 68
- Issue
- 3
- Pages
- 295-303
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1983511886
- Cited by
- 433
- References
- 20
- FWCI
- 28.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.